Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Nov;205(5):2067-2071.
doi: 10.1111/bjh.19764. Epub 2024 Sep 12.

A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma

John Kuruvilla  1 , Christopher Rushton  2 , Diego Villa  3 , Muhammad Aslam  4 , Anca Prica  1 , Nizar Abdel Samad  5 , Stephane Doucet  6 , Jill Dudebout  7 , Isabelle Fleury  8 , Graeme Fraser  9 , Jean-Francois Larouche  10 , Mona Shafey  11 , Pamela Skrabek  12 , Tanya Skamene  13 , Ryan D Morin  2 , Miguel Alcaide  2 , Susana Ben-Neriah  14 , David Lee  15 , Chad Winch  16 , Lois E Shepherd  16 , David W Scott  3 , Michael Crump  1 , Bingshu E Chen  16 , Annette E Hay  16
Affiliations
Clinical Trial

A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma

John Kuruvilla et al. Br J Haematol. 2024 Nov.

Abstract

In the LY.17 randomized phase II clinical trial, adults with relapsed and refractory diffuse large B-cell lymphoma treated with ibrutinib-R-GDP (IR-GDP) for up to three cycles had more documented bacterial and fungal infections, without improvement in overall response, compared with R-GDP. CR, complete response; DLBCL, diffuse large B-cell lymphoma; PD, progressive disease; PR, partial response; R/R, relapsed/refractory; SD, stable disease.

PubMed Disclaimer

References

REFERENCES

    1. Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy‐sensitive non‐Hodgkin's lymphoma. N Engl J Med. 1995;333(23):1540–1545.
    1. Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem‐cell transplantation for relapsed and refractory aggressive lymphomas: NCIC‐CTG LY.12. J Clin Oncol. 2014;32(31):3490–3496.
    1. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922–926.
    1. Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, et al. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. 2018;560(7718):387–391.
    1. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non‐Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068.

MeSH terms

LinkOut - more resources